{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:58:39Z","timestamp":1785301119284,"version":"3.55.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Melasma is a common hyperpigmentation disorder influenced by ultraviolet exposure, genetics, and hormonal factors. Although associations with pregnancy and oral contraceptives are well established, the impact of hormone replacement therapy (HRT) on melasma is poorly researched.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>The aim was to evaluate existing evidence on the relationship between HRT and melasma and propose evidence-based management guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS AND MATERIALS<\/jats:title>\n                    <jats:p>A literature search of PubMed, Embase, and Scopus was conducted. Studies involving oral oestrogen-only HRT, combined HRT, transdermal oestrogen, topical oestrogen, and vaginal oestrogen were included. Guidelines were proposed based on the strength of evidence available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Evidence is limited and largely comprises case reports. High-dose oral oestrogen-only HRT has the strongest documented association, with case reports suggesting an association to forearm melasma in women with Fitzpatrick types III\u2013VI. Case reports exist for combined oral and transdermal HRT, whereas topical and vaginal HRT formulations have minimal evidence to support their association with melasma. In vitro fertilization has no reported associated cases of melasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>HRT-associated melasma is underrepresented in the literature. Clinicians should counsel at-risk women on melasma risk and ensure strict photoprotection. Prospective studies are needed to clarify melasma risk across different HRT formulations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005032","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:00:45Z","timestamp":1769608845000},"page":"765-769","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Does Hormone Replacement Therapy Influence Melasma Development? A Review of the Evidence and Management Guidelines"],"prefix":"10.1097","volume":"52","author":[{"given":"Sabriya","family":"Abdeen","sequence":"first","affiliation":[{"name":"Royal Brisbane and Women's Hospital, Brisbane, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Shao","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Queensland, Brisbane, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davin","family":"Lim","sequence":"additional","affiliation":[{"name":"Cutis Dermatology, Brisbane, Australia;"},{"name":"The Melasma Clinic, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"R1-20260729","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13555-017-0194-1","article-title":"Melasma: an up-to-date comprehensive review","volume":"7","author":"Ogbechie-Godec","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R2-20260729","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13555-023-00915-1","article-title":"Self-esteem, depression, anxiety and quality of life in patients with melasma living in a sunny mediterranean area: results from a prospective cross-sectional study","volume":"13","author":"Platsidaki","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1046\/j.1365-2133.1998.02537.x","article-title":"Melasma of the arms associated with hormone replacement therapy","volume":"139","author":"Johnston","year":"1998","journal-title":"Br J Dermatol"},{"key":"R4-20260729","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5122(00)00089-X","article-title":"Hormone replacement therapy in women with pre-existing hyperpigmented lesions","volume":"35","author":"Choi","year":"2000","journal-title":"Maturitas"},{"key":"R5-20260729","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1468-3083.2010.03638.x","article-title":"Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis","volume":"24","author":"Jang","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R6-20260729","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1046\/j.1365-2133.1999.03078.x","article-title":"Melasma of the arms associated with hormone replacement therapy","volume":"141","author":"Varma","year":"1999","journal-title":"Br J Dermatol"},{"key":"R7-20260729","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1440-0960.1997.tb01097.x","article-title":"Melasma of the forearms","volume":"38","author":"O'Brien","year":"1997","journal-title":"Australas J Dermatol"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/jwh.2011.2839","article-title":"Are all estrogens created equal? A review of oral vs. transdermal therapy","volume":"21","author":"Goodman","year":"2012","journal-title":"J Women's Health"},{"key":"R9-20260729","first-page":"57","article-title":"Melasma associated with topical estrogen cream","volume":"10","author":"Snyder","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1684\/ejd.2017.3019","article-title":"Oestrogen and progesterone receptors in melanoma and nevi: an immunohistochemical study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00403-018-1861-5","article-title":"Complex segregation analysis of facial melasma in Brazil: evidence for a genetic susceptibility with a dominant pattern of segregation","volume":"310","author":"Holmo","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"R14-20260729","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ijd.17718","article-title":"Pathogenesis of melasma explained","volume":"64","author":"Ali","year":"2025","journal-title":"Int J Dermatol"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/1110-2098.192411","article-title":"A study on the effect of estrogen, progesterone, and their cutaneous receptors in the pathogenesis of melisma","volume":"29","author":"Basha","year":"2016","journal-title":"Menoufia Med J"},{"key":"R16-20260729","doi-asserted-by":"crossref","first-page":"645","DOI":"10.15562\/bmj.v7i3.1000","article-title":"Melasma characteristic in hormonal contraceptive acceptors at Kelurahan Mangga Kecamatan Medan Tuntungan, Medan-Indonesia","volume":"7","author":"Mahdalena","year":"2018","journal-title":"Bali Med J"},{"key":"R17-20260729","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.contraception.2009.03.005","article-title":"Inhibitory effects of progestogens on the estrogen stimulation of melanocytes in vitro","volume":"80","author":"Wiedemann","year":"2009","journal-title":"Contraception"},{"key":"R18-20260729","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/der2.178","article-title":"Pathogenesis of melasma","volume":"4","author":"Khanna","year":"2023","journal-title":"Dermatol Rev"},{"key":"R19-20260729","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/jid.2010.95","article-title":"Impact of long-wavelength UVA and visible light on melanocompetent skin","volume":"130","author":"Mahmoud","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R20-20260729","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jama.1967.03120090043007","article-title":"Melasma induced by oral contraceptive drugs","volume":"199","author":"Resnik","year":"1967","journal-title":"JAMA"},{"key":"R21-20260729","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.36347\/sjams.2023.v11i09.024","article-title":"Association of melasma with thyroid disorders","volume":"11","author":"Tekou","year":"2023","journal-title":"Sch J Appl Med Sci"},{"key":"R22-20260729","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/bjd.21244","article-title":"Self\u2010applied topical interventions for melasma: a systematic review and meta\u2010analysis of data from randomized, investigator\u2010blinded clinical trials","volume":"187","author":"Pennitz","year":"2022","journal-title":"Br J Dermatol"},{"key":"R23-20260729","first-page":"578","article-title":"Chemical peels in melasma: a review with consensus recommendations by Indian Pigmentary Expert Group","volume":"62","author":"Sarkar","year":"2017","journal-title":"Indian J Dermatol"},{"key":"R24-20260729","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/der2.177","article-title":"Energy-based devices for melasma and postinflammatory hyperpigmentation","volume":"4","author":"Reynal","year":"2023","journal-title":"Dermatol Rev"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:02:04Z","timestamp":1785297724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005032","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}